{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,2]],"date-time":"2026-07-02T09:12:24Z","timestamp":1782983544162,"version":"3.54.5"},"reference-count":24,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2023,7,4]],"date-time":"2023-07-04T00:00:00Z","timestamp":1688428800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100010564","name":"Deutsches Zentrum f\u00fcr Lungenforschung","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100010564","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Pharmacol."],"abstract":"<jats:p><jats:bold>Introduction:<\/jats:bold> Triple-combination cystic fibrosis transmembrane conductance regulator (CFTR) modulator therapy with elexacaftor\/tezacaftor\/ivacaftor (ETI) was introduced in August 2020 in Germany for people with CF (pwCF) \u226512\u00a0years (yrs.) of age and in June 2021 for pwCF \u22656\u00a0yrs of age. In this single-center study, we analyzed longitudinal data on the percent-predicted forced expiratory volume (ppFEV1) and body-mass-index (BMI) for 12\u00a0months (mo.) after initiation of ETI by linear mixed models and regression analyses to identify age- and severity-dependent determinants of response to ETI.<\/jats:p><jats:p><jats:bold>Methods:<\/jats:bold> We obtained data on 42 children \u22656\u201311\u00a0yrs, 41 adolescents \u226512\u201317\u00a0yrs, and 143 adults by spirometry and anthropometry prior to ETI, and 3 and 12\u00a0mo. after ETI initiation. Data were stratified by the age group and further sub-divided into age-specific ppFEV1 impairment. To achieve this, the age strata were divided into three groups, each according to their baseline ppFEV1: lowest 25%, middle 50%, and top 25% of ppFEV1.<\/jats:p><jats:p><jats:bold>Results:<\/jats:bold> Adolescents and children with more severe lung disease prior to ETI (within the lowest 25% of age-specific ppFEV1) showed higher improvements in lung function than adults in this severity group (+18.5 vs. +7.5; <jats:italic>p<\/jats:italic> = 0.002 after 3\u00a0mo. and +13.8 vs. +7.2; <jats:italic>p<\/jats:italic> = 0.012 after 12\u00a0mo. of ETI therapy for \u226512\u201317\u00a0years and +19.8 vs. +7.5; <jats:italic>p<\/jats:italic> = 0.007 after 3\u00a0mo. for children \u22656\u201311\u00a0yrs). In all age groups, participants with more severe lung disease showed higher BMI gains than those with medium or good lung function (within the middle 50% or top 25% of age-specific ppFEV1). Regression analyses identified age as a predictive factor for FEV1 increase at 3\u00a0mo. after ETI initiation, and age and ppFEV1 at ETI initiation as predictive factors for FEV1 increase 12\u00a0mo. after ETI initiation.<\/jats:p><jats:p><jats:bold>Discussion:<\/jats:bold> We report initial data, which suggest that clinical response toward ETI depends on age and lung disease severity prior to ETI initiation, which argue for early initiation of ETI.<\/jats:p>","DOI":"10.3389\/fphar.2023.1171544","type":"journal-article","created":{"date-parts":[[2023,7,4]],"date-time":"2023-07-04T07:11:09Z","timestamp":1688454669000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":13,"title":["Spirometric and anthropometric improvements in response to elexacaftor\/tezacaftor\/ivacaftor depending on age and lung disease severity"],"prefix":"10.3389","volume":"14","author":[{"given":"Katharina","family":"Sch\u00fctz","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sophia Theres","family":"Pallenberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julia","family":"Kontsendorn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"DeLuca","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cinja","family":"Sukdolak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rebecca","family":"Minso","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tina","family":"B\u00fcttner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martin","family":"Wetzke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christian","family":"Dopfer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Annette","family":"Sauer-Heilborn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Felix C.","family":"Ringshausen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sibylle","family":"Junge","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Burkhard","family":"T\u00fcmmler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gesine","family":"Hansen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna-Maria","family":"Dittrich","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2023,7,4]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"e7","DOI":"10.1016\/j.jcf.2020.05.004","article-title":"Females with cystic fibrosis have a larger decrease in sweat chloride in response to lumacaftor\/ivacaftor compared to males","volume":"20","author":"Aalbers","year":"2021","journal-title":"J. Cyst. Fibros."},{"key":"B2","doi-asserted-by":"publisher","first-page":"744705","DOI":"10.3389\/fped.2021.744705","article-title":"Long-term outcomes in real life of lumacaftor-ivacaftor treatment in adolescents with cystic fibrosis","volume":"9","author":"Bui","year":"2021","journal-title":"Front. Pediatr."},{"key":"B3","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1164\/rccm.202011-4153OC","article-title":"Rapid improvement after starting elexacaftor-tezacaftor-ivacaftor in patients with cystic fibrosis and advanced pulmonary disease","volume":"204","author":"Burgel","year":"2021","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"B4","doi-asserted-by":"publisher","first-page":"1021","DOI":"10.3390\/jcm11041021","article-title":"Elexacaftor\/Tezacaftor\/Ivacaftor in Patients with Cystic Fibrosis Homozygous for the F508del Mutation and Advanced Lung Disease: A 48-Week Observational Study","volume":"11","author":"Carnovale","year":"2022","journal-title":"J. Clin. Med."},{"key":"B5","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1016\/S2213-2600(15)00545-7","article-title":"Safety, pharmacokinetics, and pharmacodynamics of ivacaftor in patients aged 2\u20135 years with cystic fibrosis and a CFTR gating mutation (KIWI): An open-label, single-arm study","volume":"4","author":"Davies","year":"2016","journal-title":"Lancet Respir. Med."},{"key":"B6","doi-asserted-by":"publisher","first-page":"585","DOI":"10.1164\/rccm.202008-3177OC","article-title":"Ivacaftor in infants aged 4 to <12 months with cystic fibrosis and a gating mutation. Results of a two-part phase 3 clinical trial","volume":"203","author":"Davies","year":"2021","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"B7","doi-asserted-by":"publisher","first-page":"00464","DOI":"10.1183\/23120541.00464-2022","article-title":"Dual CFTR modulator therapy efficacy in the real world: Lessons for the future","volume":"8","author":"Dittrich","year":"2022","journal-title":"ERJ Open Res."},{"key":"B8","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1378\/chest.12-1430","article-title":"Change in sweat chloride as a clinical end point in cystic fibrosis clinical trials: The ivacaftor experience","volume":"143","author":"Durmowicz","year":"2013","journal-title":"Chest"},{"key":"B9","doi-asserted-by":"publisher","first-page":"971","DOI":"10.1513\/AnnalsATS.202008-1054OC","article-title":"Effects of lumacaftor\u2013ivacaftor on lung clearance index, magnetic resonance imaging, and airway microbiome in Phe508del homozygous patients with cystic fibrosis","volume":"18","author":"Graeber","year":"2021","journal-title":"Ann. Am. Thorac. Soc."},{"key":"B10","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1164\/rccm.202201-0219oc","article-title":"Effects of elexacaftor\/tezacaftor\/ivacaftor therapy on lung clearance index and magnetic resonance imaging in patients with cystic fibrosis and one or two F508del alleles","volume":"206","author":"Graeber","year":"","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"B11","doi-asserted-by":"publisher","first-page":"540","DOI":"10.1164\/rccm.202110-2249OC","article-title":"Effects of elexacaftor\/tezacaftor\/ivacaftor therapy on CFTR function in patients with cystic fibrosis and one or two F508del alleles","volume":"205","author":"Graeber","year":"","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"B12","doi-asserted-by":"publisher","first-page":"1940","DOI":"10.1016\/S0140-6736(19)32597-8","article-title":"Efficacy and safety of the elexacaftor plus tezacaftor plus ivacaftor combination regimen in people with cystic fibrosis homozygous for the F508del mutation: A double-blind, randomised, phase 3 trial","volume":"394","author":"Heijerman","year":"2019","journal-title":"Lancet"},{"key":"B13","doi-asserted-by":"publisher","first-page":"S1569","DOI":"10.1016\/j.jcf.2022.12.009","article-title":"Effect of Elexacaftor\/Tezacaftor\/Ivacaftor on annual rate of lung function decline in people with cystic fibrosis","volume":"2022","author":"Lee","year":"2022","journal-title":"J. Cyst. Fibros."},{"key":"B14","doi-asserted-by":"publisher","first-page":"325","DOI":"10.1016\/S2213-2600(18)30460-0","article-title":"Safety, pharmacokinetics, and pharmacodynamics of lumacaftor and ivacaftor combination therapy in children aged 2\u20135 years with cystic fibrosis homozygous for F508del-CFTR: An open-label phase 3 study","volume":"7","author":"McNamara","year":"2019","journal-title":"Lancet Respir. Med."},{"key":"B15","doi-asserted-by":"publisher","first-page":"S33","DOI":"10.1016\/S1569-1993(22)00251-X","article-title":"WS17.03 initiating ivacaftor (IVA) at younger vs older ages improves pulmonary outcomes in people with cystic fibrosis (pwCF): A long-term real-world study","volume":"21","author":"Merlo","year":"2022","journal-title":"J. Cyst. Fibros."},{"key":"B16","doi-asserted-by":"publisher","first-page":"S13","DOI":"10.1016\/S1569-1993(22)00190-4","article-title":"WS07.02 lumacaftor\/ivacaftor in people with cystic fibrosis: Factors predisposing the response and impact on lung function decline","volume":"21","author":"Mesinele","year":"2022","journal-title":"J. Cyst. Fibros."},{"key":"B17","doi-asserted-by":"publisher","first-page":"1809","DOI":"10.1056\/NEJMoa1908639","article-title":"Elexacaftor-Tezacaftor-Ivacaftor for cystic fibrosis with a single Phe508del allele","volume":"381","author":"Middleton","year":"2019","journal-title":"N. Engl. J. Med."},{"key":"B18","doi-asserted-by":"publisher","first-page":"1376","DOI":"10.3390\/jpm11121376","article-title":"Prediction of real-world long-term outcomes of people with CF homozygous for the F508del mutation treated with CFTR modulators","volume":"11","author":"Muilwijk","year":"2021","journal-title":"J. Pers. Med."},{"key":"B19","doi-asserted-by":"publisher","first-page":"00204","DOI":"10.1183\/23120541.00204-2022","article-title":"Long-term effectiveness of dual CFTR modulator treatment of cystic fibrosis","volume":"8","author":"Muilwijk","year":"2022","journal-title":"ERJ Open Res."},{"key":"B20","doi-asserted-by":"publisher","first-page":"529","DOI":"10.1164\/rccm.202108-1986OC","article-title":"Clinical effectiveness of elexacaftor\/tezacaftor\/ivacaftor in people with cystic fibrosis: A clinical trial","volume":"205","author":"Nichols","year":"2022","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"B21","doi-asserted-by":"publisher","first-page":"1324","DOI":"10.1183\/09031936.00080312","article-title":"Multi-ethnic reference values for spirometry for the 3\u201395-yr age range: The global lung function 2012 equations","volume":"40","author":"Quanjer","year":"2012","journal-title":"Eur. Respir. J."},{"key":"B22","doi-asserted-by":"publisher","first-page":"545","DOI":"10.1016\/S2213-2600(18)30202-9","article-title":"Ivacaftor treatment of cystic fibrosis in children aged 12 to <24months and with a CFTR gating mutation (ARRIVAL): A phase 3 single-arm study","volume":"6","author":"Rosenfeld","year":"2018","journal-title":"Lancet Respir. Med."},{"key":"B23","doi-asserted-by":"publisher","first-page":"996","DOI":"10.1164\/rccm.201909-1845LE","article-title":"Females with cystic fibrosis demonstrate a differential response profile to ivacaftor compared with males","volume":"201","author":"Secunda","year":"2020","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"B24","doi-asserted-by":"publisher","first-page":"1522","DOI":"10.1164\/rccm.202102-0509OC","article-title":"A Phase 3 Open-Label Study of Elexacaftor\/Tezacaftor\/Ivacaftor in Children 6 through 11 Years of Age with Cystic Fibrosis and at Least One F508del Allele","volume":"203","author":"Zemanick","year":"2021","journal-title":"Am. J. Respir. Crit. Care Med."}],"container-title":["Frontiers in Pharmacology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2023.1171544\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,7,4]],"date-time":"2023-07-04T07:11:12Z","timestamp":1688454672000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2023.1171544\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,7,4]]},"references-count":24,"alternative-id":["10.3389\/fphar.2023.1171544"],"URL":"https:\/\/doi.org\/10.3389\/fphar.2023.1171544","relation":{},"ISSN":["1663-9812"],"issn-type":[{"value":"1663-9812","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,7,4]]},"article-number":"1171544"}}